Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
August 05 2024 - 4:05PM
Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage
biopharmaceutical company focused on developing medicines to target
hypertension, chronic kidney disease (CKD) and other diseases
driven by dysregulated aldosterone, today announced it will report
its financial results from the second quarter ended June 30, 2024,
after the financial markets close on Tuesday, August 13, 2024.
Tuesday, August 13th @
4:30 p.m. ET |
Domestic: |
1-877-407-9127 |
International: |
1-201-689-8574 |
Webcast: |
Link |
|
|
A live webcast of the conference call may be found here or on
the “News & Events” page in the Investor Relations section of
the Mineralys Therapeutics website.
About Mineralys TherapeuticsMineralys
Therapeutics is a clinical-stage biopharmaceutical company focused
on developing medicines to target hypertension, CKD and other
diseases driven by dysregulated aldosterone. Its initial product
candidate, lorundrostat, is a proprietary, orally administered,
highly selective aldosterone synthase inhibitor that Mineralys
Therapeutics is developing for cardiorenal conditions affected by
dysregulated aldosterone, including hypertension and CKD. Mineralys
is based in Radnor, Pennsylvania, and was founded by Catalys
Pacific. For more information, please
visit https://mineralystx.com. Follow Mineralys
on LinkedIn and Twitter.
Contact:
Investor
Relationsinvestorrelations@mineralystx.com
Media RelationsTom WeibleElixir
Health Public RelationsPhone: (1) 515-707-9678Email:
tweible@elixirhealthpr.com
Mineralys Therapeutics (NASDAQ:MLYS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Mineralys Therapeutics (NASDAQ:MLYS)
Historical Stock Chart
From Oct 2023 to Oct 2024